Flatiron Health and Massive Bio Partner to Revolutionize Cancer Trial Recruitment

Flatiron Health, an oncology health tech firm and Roche Group affiliate, has announced a groundbreaking partnership with Massive Bio to enhance patient recruitment for clinical trials. The collaboration, revealed on April 7, 2025, aims to leverage Massive Bio's extensive patient database to identify and enroll suitable candidates for oncology studies.

Streamlining Patient Identification and Enrollment

Under the new agreement, Flatiron Health will gain access to Massive Bio's database on a per-study basis. This arrangement allows Flatiron to pinpoint potential trial participants who reside near clinical research sites but are not currently engaged in any studies. Once identified, these patients will be referred to research facilities within Flatiron's network and matched with appropriate clinical trials.

Dr. Arturo Loaiza-Bonilla, co-founder and chief medical officer of Massive Bio, emphasized the potential impact of this partnership: "By pairing our AI-driven platform and concierge services with Flatiron Health's extensive research infrastructure, we can help physicians and care teams expedite trial enrollment, reduce disparities in access and improve outcomes for more patients."

Expanding Research Capabilities

This collaboration marks Flatiron Health's latest initiative to broaden its research scope. In a previous move, the New York-based company forged an alliance with NRG Oncology, a research consortium affiliated with the National Clinical Trials Network at the National Cancer Institute. This earlier partnership aimed to implement Flatiron's data capture tool in a multicenter trial setting.

Meanwhile, Massive Bio has reaffirmed its commitment to increasing access to cancer trials, particularly in light of recent changes in health policy. The company, which originated from a small business grant provided by the National Institutes of Health (NIH), has expressed its dedication to this mission despite the challenges faced by the NIH, including significant layoffs and grant terminations.